Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. by Donohue, JF et al.
Accepted Manuscript
Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23
clinical trials in patients with chronic obstructive pulmonary disease
James F. Donohue, Paul W. Jones, Christian Bartels, Jessica Marvel, Peter
D'Andrea, Donald Banerji, David G. Morris, Francesco Patalano, Robert Fogel
PII: S1094-5539(17)30237-7
DOI: 10.1016/j.pupt.2017.12.005
Reference: YPUPT 1690
To appear in: Pulmonary Pharmacology & Therapeutics
Received Date: 24 September 2017
Revised Date: 6 December 2017
Accepted Date: 15 December 2017
Please cite this article as: Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, Morris
DG, Patalano F, Fogel R, Correlations between FEV1 and patient-reported outcomes: A pooled analysis
of 23 clinical trials in patients with chronic obstructive pulmonary disease, Pulmonary Pharmacology &
Therapeutics (2018), doi: 10.1016/j.pupt.2017.12.005.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
1 
 
Correlations between FEV1 and Patient-Reported Outcomes: a 
Pooled Analysis of 23 Clinical Trials in Patients with Chronic 
Obstructive Pulmonary Disease 
James F Donohuea*, Paul W Jonesb, Christian Bartelsc, Jessica Marveld, Peter D’Andread, 
Donald Banerjid, David G Morrisc, Francesco Patalanoc, Robert Fogeld 
Author Details: 
aDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, 
School of Medicine, Chapel Hill, NC, USA. bDivision of Clinical Science, St George’s, 
University of London, London, UK. cNovartis Pharma AG, Basel, Switzerland. dNovartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA. 
*Correspondence: James F. Donohue, MD, FCCP, Department of Pulmonary Diseases and 
Critical Care Medicine, The University of North Carolina at Chapel Hill, CB# 7020, 130 
Mason Farm Rd, Chapel Hill, NC 27599; e-mail: jdonohue@med.unc.edu  
Portions of the data have been presented in poster format at the Population Approach Group 
Europe Congress, June 2-5, 2015, Crete Greece, and in abstract form at ERS 2015, 
September 26-30, Amsterdam, Holland (Donohue JF, Jones PW, Bartels C, Marvel J, 
D’Andrea P, Banerji D, Patalano F and Fogel R. European Respiratory Journal 
2015;46[suppl 59] DOI: 10.1183/13993003.congress-2015.PA1013) and CHEST 2015, 
October 24-28, 2015, Montreal, Canada (Donohue JF, Bartels C, Patalano F, Marvel J, 
D’Andrea P, Banerji D and Fogel R. Chest. 2015;148[4_MeetingAbstracts]:719A). 
 
Figures/Tables: 3 figures/2 tables; plus 2 supplementary figures/4 supplementary tables 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
2 
 
ABSTRACT  
BACKGROUND: In clinical trials of inhaled bronchodilators, chronic obstructive pulmonary 
disease (COPD) guidelines recommend that patient-reported outcomes (PROs) are 
assessed alongside lung function. How these endpoints are related is unclear. 
METHODS: Pooled longitudinal data from 23 randomised controlled COPD studies were 
analyzed (N=23,213). Treatments included long-acting β2 agonists, long-acting muscarinic 
antagonists (LABAs or LAMAs) and the LABA/LAMA combination QVA149. Outcome 
measures were Transition Dyspnoea Index (TDI) and St. George’s Respiratory 
Questionnaire (SGRQ) scores, COPD exacerbation frequency and rescue medication use. 
Relationships between changes in trough forced expiratory volume in one second (∆FEV1) 
and outcomes following treatment were assessed using correlations of data summaries and 
model-based analysis: generalized linear mixed-effect regression modeling to determine if 
∆FEV1 could predict patient outcomes with different treatments.  
RESULTS: Mean age was 64 years, 73% were male, and most had moderate (45%) or 
severe (52%) disease. Statistically significant correlations were observed between ∆FEV1 
and each outcome measure (exacerbations Rs = 0.05; rescue medication, SGRQ, TDI, r = 
0.11-0.16; all p < 0.001). Patients with greater improvements in trough FEV1 had on average 
better SGRQ and TDI scores, fewer exacerbations, and used less rescue medication. For 
SGRQ and TDI scores, minimal clinically important differences were observed over the 
range of pooled ∆FEV1 values. Model-based predictions confirmed the treatment effect was 
partly explained by changes in FEV1 from baseline with improvements in PROs observed 
across all treatments when trough FEV1 improved. Across all endpoints active treatments 
were better than placebo (p < 0.0001), and LABA/LAMA treatment resulted in numerically 
better treatment outcomes than either monocomponent.  
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CONCLUSIONS: These data suggest that FEV1 improvements post-bronchodilation 
correlate with PRO improvements. Further improvements in patient outcomes may be 
expected by maximizing lung function improvements. 
TRIAL REGISTRATION: Registration details for the 23 randomised controlled studies used 
in this pooled analysis are supplied in Additional File 4.  
KEY WORDS: COPD; PROs; FEV1; TDI; SGRQ; regression modelling.  
 
1. INTRODUCTION  
Inhaled long-acting bronchodilators are the mainstay in managing chronic obstructive 
pulmonary disease (COPD), improving lung function, health status, symptoms, and reducing 
exacerbations.[1, 2] For the majority of symptomatic COPD patients, dual bronchodilation 
using a long-acting β2 agonist (LABA) combined with a long-acting muscarinic antagonist 
(LAMAs) is recommended.[3] Inhaled corticosteroids (ICS) are also commonly used in the 
management of symptomatic COPD patients.[2] However the literature is evolving about the 
exact role of ICS in the treatment of COPD.[4, 5]  
Measurement of lung function by spirometry, particularly the forced expiratory volume in one 
second (FEV1), is routinely used as an indicator of efficacy in the evaluation of 
bronchodilators.[4] However, COPD is a complex disease with multiple symptoms, not all of 
which can be reflected by spirometry.[5] As such, the exclusive use of FEV1 as the primary 
efficacy endpoint has increasingly become questioned, as it may underestimate the true 
clinical benefit of the intervention under test.[6, 7] To healthcare professionals, evaluation of 
patient-reported outcomes (PROs) is of more relevance than isolated lung function data, as 
these represent the impact of treatment from the patient’s perspective.[8] Indeed, the use of 
PROs such as health status measurement as co-primary endpoints in COPD trials is now 
recommended in COPD guidelines.[9] Such data are increasingly being requested by payers 
and other decision-makers to understand how changes in lung function relate to quality of 
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life, and how they might impact COPD-related healthcare resource use.[10] The Transition 
Dyspnoea Index (TDI) measures change in dyspnea from baseline. The St. George’s 
Respiratory Questionnaire (SGRQ), a measure of health-related quality of life, captures 
symptoms, impact on patient well-being, and activities of daily living. The minimal clinical 
important difference (MCID) for TDI is an improvement of >1 unit in the TDI total score and 
the MCID for SGRQ is a change of 4 units in the SGRQ total score. [11] PRO instruments, 
along with patient-recorded rescue medication use and COPD exacerbations are now 
regularly measured alongside functional measurements such as FEV1 in clinical trials to 
provide an overall assessment of the effect of therapies on COPD patients. 
Previous COPD studies have shown FEV1 to be a predictor of future morbidity and 
mortality,[12] patient outcomes,[13-17] rescue medication use,[16, 17] and exacerbation 
frequency.[17] Most of these studies, however, have included data from patients treated with 
single-agent LABA or LAMA therapies rather than LABA/LAMA combinations. Furthermore, 
they were unable to detect whether a “plateau” or “ceiling” effect existed in the relationship 
between improvement in lung function and clinical endpoints that might occur with very large 
improvements. 
The aim of this study was to characterise, in a large cohort of patients (N=23,213) from 23 
clinical trials, the relationship between changes from baseline in trough FEV1 (∆FEV1) and 
patient outcomes in COPD patients treated with LABAs, LAMAs and the dual LABA/LAMA 
bronchodilator QVA149. 
 
2. METHODS 
2.1. Study design and data selection 
The investigation was a pooled analysis of data from patients enrolled in 23 randomised, 
parallel-group, placebo- or active-controlled studies in COPD patients (Table 1; Additional 
file 3: Tables S1 to S3). The studies were between 3 and 18 months’ duration and were 
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conducted by Novartis. Each study provided data on trough FEV1 and patient outcomes, and 
included at least one intervention treatment arm. Interventions and doses used were the 
LABAs indacaterol (IND; 27.5 µg twice daily [b.i.d.] or 75/150/300 or 600 µg once daily 
[o.d.]), salmeterol (50 µg b.i.d.) and formoterol (12 µg b.i.d.); the LAMAs glycopyrronium 
(GLY; 12.5 µg b.i.d. [15.6 µg if glycopyrrolate, the bromide salt, was used] or 50 µg o.d.) and 
tiotropium (18 µg o.d.); and the IND/GLY combination QVA149 (27.5/12.5 µg b.i.d., 110/50 
µg o.d. fixed doses or 150/50 µg o.d. co-administration). Full clinical trial reports were 
available for each of the studies, and in the majority of cases the methods and main findings 
have been reported elsewhere (Table 1). Our analysis focused on moderate and severe 
exacerbations (i.e., exacerbations that required additional medication or hospitalization). 
Symptomatic events that were not treated were classified as mild, and were excluded from 
the analysis. 
Each study was conducted in accordance with ICH Harmonised Tripartite Guidelines for 
Good Clinical Practice, with local regulations applied, and the Declaration of Helsinki.  
2.2. Patients 
Enrolled patients were male or female, aged ≥ 40 years, and were current or former smokers 
with a confirmed diagnosis of COPD. All patients with available trough FEV1 measurements 
were included in the analysis.  
2.3. Endpoints  
The primary objective of the analysis was to define the relationship between ∆FEV1 and the 
following patient outcomes: health status and dyspnea (as assessed by SGRQ and TDI), 
disease exacerbations, and rescue medication use (number of self-reported salbutamol 
puffs/day). 
All trough FEV1 measurements recorded during treatment were pooled into the data set. In 
general, trough FEV1 at baseline was defined as the average of FEV1 values recorded 50 
and 15 minutes prior to the first dose of study drug; trough FEV1 during treatment was 
recorded as the average of the 23 h 10 min and 23 h 45 min post-dose values. Spirometry 
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was conducted in each study in accordance with American Thoracic Society/European 
Respiratory Society (ATS/ERS) standards.[18] 
Symptoms were recorded in electronic diaries: exacerbations of COPD were defined as the 
onset or worsening of more than one respiratory symptom for >3 consecutive days, or those 
that required intervention (e.g. systemic steroids, antibiotics, oxygen) and/or hospitalization 
or emergency room visits. Severe exacerbations were defined as those requiring 
hospitalization. In some studies, exacerbations were captured as safety endpoints (adverse 
events) and in others as efficacy endpoints. 
Data for ∆FEV1, ∆SGRQ, TDI and rescue medication use were pooled as longitudinal data, 
with each measurement associated to the time relative to treatment start at which the 
measurement was recorded. Minimal clinically important differences in SGRQ and TDI 
scores were described using thresholds of ≥4 units and ≥1 unit, respectively.[19, 20] 
Exacerbations were pooled as the number of moderate or severe exacerbations per patient 
together with the total treatment duration of each patient.  
2.4. Analysis Methods 
Relationships between PROs and ∆FEV1 were examined using data summarization and 
model-based analysis. Pooled data were summarised using descriptive statistics of 
correlations, and presented graphically. Correlation coefficients were computed between the 
summarised endpoints for each patient for ∆FEV1 and outcomes; Spearman rank correlation 
coefficient was used for exacerbations and Pearson correlation coefficient for TDI, ∆SGRQ 
and rescue medication use.  
Regression modelling was performed to determine if changes in trough FEV1 could predict 
improvements in patient outcomes observed with different treatments. Linear and 
generalised linear mixed-effect models [21-23] were used to describe the different endpoints. 
For SGRQ and TDI, linear longitudinal models were used, describing baseline, treatment 
efficacy and drift, and including between-subject variability. For rescue medication use and 
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exacerbations, an overdispersed Poisson model was used with the overdispersion being 
expressed as between-subject variability. (An extended methodology section is provided in 
Additional File 1.) 
2.5. Covariate modelling 
Differences between studies, treatment classes and treatments were included in the initial 
base model as fixed effects. Predictors of treatment efficacy were systematically tested for 
inclusion, including interactions differentiating predictors by treatment class. Categorical 
predictors comprised any exacerbation in the previous 12 months; severity of disease 
(based on Global initiative for chronic Obstructive Lung Disease [GOLD] stages[2]); smoking 
history; inhaled corticosteroids (yes/no); and gender. Continuous predictors comprised age; 
weight; SGRQ score at baseline; FEV1 at baseline; rescue medication use at baseline; 
baseline dyspnea index (BDI); predicted FEV1; FEV1 baseline as percent of predicted FEV1; 
and reversibility with a short-acting β2 agonist (%). 
Change in trough FEV1 from baseline was included as a predictor for SGRQ, TDI, rescue 
medication and exacerbations. As described by Jones et al,[17] the effect of positive and 
negative changes in trough FEV1 on SGRQ was estimated as a linear relationship with a 
breakpoint at ∆FEV1 equivalent to 0, using two separate regression coefficients.  
2.6. Model analysis of simulated data assuming a high association 
between lung function, FEV1 and patient outcomes 
Regression analysis when performed with an explanatory variable that is measured with 
error, such as ∆FEV1, is known to lead to a downward bias in the estimated effect of the 
explanatory variable on the response [24]. ∆FEV1 is measured with large error of a 
magnitude similar to treatment effects and so its explanatory power of the response may 
appear to be less than it actually is. To explore this phenomenon, data were simulated 
assuming a high association between mean improvement of lung function (∆FEV1) and 
patient outcomes.  Two analyses were performed, in which the simulated ∆FEV1 data was 
either the true ∆FEV1 values, or in the second analysis ∆FEV1 included measurement error. 
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Both sets of simulated data were analyzed using the same regression model as for the 
observed clinical data in order to assess the impact of ∆FEV1 measurement error on the 
estimated strength of association between ∆FEV1 and the response variable. 
3. RESULTS 
3.1 Patient characteristics 
Data from 23,213 patients were included in the analyses. The mean age of the patients was 
64 years, 73% were male and the majority had either moderate (45%) or severe (52%) 
disease (Table 2). Two studies included in the overall cohort comprised patients with more 
severe disease (>98% patients with prior exacerbation; mean FEV1 at baseline ~35% of 
predicted). 
3.2 Data summaries and related inferences 
The pooled trough FEV1 data shown in Figure S1 illustrates the degree of variability of the 
FEV1 within treatment groups; The 80 percentile of the placebo response extends beyond 
the median response of the active treatments. The 2nd and 3rd order polynomials showed a 
significant improvement of fit to the model above a linear regression, but since this was small 
(0.18% of variance at most; Additional File 2; Figure S2), linear regressions have been 
reported here. Correlation coefficients between trough FEV1 change from baseline and other 
endpoints were statistically significantly different from zero as follows: exacerbations Rs = -
0.05; rescue medication, SGRQ, TDI, r = 0.11-0.16 (all p < 0.001) (Figure 1; Additional file 3: 
Table S4). The magnitude of the relationship between trough FEV1 change from baseline 
and other endpoints can be assessed from Figure 1, which shows mean values of the 
endpoints for patients grouped according to their response in FEV1 change from baseline. A 
clear relationship is seen, and the magnitude of the relationship is clinically non-negligible. 
Minimal clinically important differences in SGRQ and TDI scores were observed over the 
range of ∆FEV1 values observed in the pooled data; for example, for SGRQ the score 
between the decile of patients with the lowest and highest response in FEV1 differed by 7.1 
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(Figure 1). A sensitivity analysis that included only studies with 12-month duration or longer 
was performed and the results did not change the findings (data not shown). 
There was no obvious evidence of a plateau effect: greater improvements in trough FEV1 
were associated with better SGRQ and TDI scores, less rescue medication and fewer 
exacerbations. Nevertheless, very few measurements were recorded at the extreme values 
of FEV1 change so the existence of a plateau cannot be excluded. 
Regression modelling was performed to determine if changes in FEV1 predicted 
improvements in patient outcomes observed with different treatment options. Models were 
fitted using FEV1 change from baseline as a predictor for changes in patient outcomes from 
baseline. Model-based predictions compared the efficacy observed in different patients 
receiving active treatment, and confirmed that part of the treatment effect can be explained 
by changes in FEV1 from baseline (Figure 2). Improvements in PROs were observed across 
all treatment arms whenever an improvement in trough FEV1 was observed. In general, 
treatments with higher improvements in trough FEV1 resulted in larger improvements in 
patient outcomes; hence, LABA/LAMA treatment tended to be superior to either 
monotherapy, which each had roughly equivalent effects, and all treatments were superior to 
placebo. However, for TDI and rescue medication use, improvements in outcomes with 
LABA treatment were similar to those observed with LABA/LAMA treatment yet trough FEV1 
improvement was comparatively reduced. By calculating and comparing the efficacy of 
patients who exhibited no FEV1 response with those exhibiting FEV1 responses typical for 
the treatment class (Figure 2), it was estimated that between 5 and 35% of the overall 
treatment effect could be explained by changes in FEV1, with SGRQ and TDI scores most 
associated, and rescue medication least associated. Thus, while the treatment effect can be 
partly explained by changes in FEV1 from baseline, there remains a sizeable proportion of 
the benefit that is not predicted by FEV1 changes. 
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All treatment options were better than placebo across all endpoints (p < 0.0001). LABA and 
LAMA treatments had comparable efficacy for the SGRQ endpoint, while for the other 
endpoints, differences between LAMA and LABA treatments were observed. LABA 
treatment provided greater reduction in rescue medication use than LAMA treatment (p < 
0.0001), and a trend towards improvements in TDI scores (p = 0.2). Conversely, for 
exacerbation reduction, a greater effect with LAMA versus LABA treatments (p = 0.6) was 
detectable. Across all endpoints, the LABA/LAMA combination resulted in numerically better 
treatment outcomes than either LABA or LAMA monotherapies. At a p-value of 0.05, 
differences between LABA/LAMA combination and monotherapies were significant for 
SGRQ versus both LABA and LAMA, for TDI versus LAMA, for exacerbations versus LABA, 
and for rescue medication versus LAMA. This shows that the mechanisms of action of the 
LAMA and LABA drug classes complement each other. 
In a sub-analysis of patients who completed 12 weeks of treatment, a substantial proportion 
of patients receiving LABA/LAMA treatment (56 patients; 23.7%) experienced large 
improvements in both lung function (∆FEV1 >300 ml) and quality of life (≥5 unit decrease in 
SGRQ). The equivalent data for patients in other treatment arms were GLY (36 patients; 
15.3%); IND (26 patients; 11.2%); and placebo (3 patients; 1.4%). 
The regression analysis results of data simulated using the assumption of a known strong 
association between endpoints were similar to the results obtained from the models of the 
clinical data: A sizeable proportion of the benefit was not predicted by changes in FEV1 
(Figure 3a). This compares to Figure 3b where the regression analysis was performed on 
simulated ∆FEV1 data that assumed in addition that there was no measurement error in 
∆FEV1. This produced a model in which the efficacy in SGRQ scores can be attributed 
entirely to changes in FEV1 (Figure 3b). This is seen as the change in SGRQ is described by 
changes in ∆FEV1 only and not by differences between treatments.   
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4 DISCUSSION 
Our data suggest that, at a population level, improvements in FEV1 post-bronchodilation 
correlate with improvements in SGRQ, TDI and exacerbation rate endpoints, which are each 
of relevance to patients, physicians and payers. FEV1 as an endpoint is also a regulatory 
requirement in the approval of bronchodilators, and an integral part of major treatment 
guidelines. 
In the current analysis, pooled FEV1 and patient outcome data from 23,213 patients in 23 
studies confirmed that, at least at a population level, statistically significant and clinically 
important relationships exist between improvements in trough FEV1 and COPD outcomes 
over 12 to 78 weeks of treatment.  
Our results are consistent with earlier correlative analyses of changes in FEV1 with changes 
in outcomes in patients with COPD.[17, 25] A systematic review of 22 COPD studies also 
recently confirmed that FEV1 increases were associated with statistically significant 
reductions in SGRQ.[13] 
In our analysis, correlations were established using a variety of methodologies. Graphical 
representation of raw data was used to illustrate correlations between endpoints. Here, 
improvement of FEV1 upon treatment with bronchodilators correlated with improvements in 
SGRQ and TDI as well as exacerbation rate and rescue medication use. We also modelled 
treatment efficacy as a function of treatment and observed improvements in FEV1. Using this 
approach, the average change in FEV1 from baseline was predictive for efficacy of other 
endpoints, with part of the treatment efficacy explained by improvements in FEV1. 
Treatments inducing greater improvements in FEV1 also tended to be associated with better 
responses in patient outcomes, and similarly, patients with greater FEV1 response also 
tended to have better patient outcomes. In addition to the aggregate response of the 
population, which is quite robust, it was intriguing to note that a substantial number of 
individual patients (particularly those treated with the combination LAMA/LABA treatment 
regimen) experienced large improvements in both lung function and outcomes. 
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In the regression models, a sizeable proportion of the benefit occurred without a change in 
FEV1, in particular for rescue medication use and exacerbations. Different factors could 
contribute to the observed benefits that are not predicted by changes in FEV1, potentially 
including aspects of treatment unrelated to bronchodilation, differences in placebo 
responses, and limitations of the regression models. Limitations of the correlation analysis 
include the large residual variability in the chosen endpoints and confounding of different 
effects (e.g., patient outcomes are dependent on treatment, disease severity, baseline 
values, study, FEV1 change, etc). The implication of these limitations is that correlations may 
be underestimated making it difficult to assess whether aspects of treatment unrelated to 
bronchodilation are important for patient outcomes. To quantify possible contributions, 
SGRQ and FEV1 data were simulated assuming a strong association between the two 
endpoints. The generated data were analyzed and found to be similar to the analysis results 
of the observed data in that a significant intercept shift was present, ie, an improvement 
without change in FEV1.  
With regard to COPD exacerbation rate, our data show that part of the efficacy on 
exacerbation reduction was due to bronchodilation following treatment. Nevertheless, ∆FEV1 
predicted a smaller fraction (approximately one-third) of the efficacy for exacerbations than 
for SGRQ and TDI suggesting that aspects of the treatment other than lung function 
improvement could be important in reducing exacerbations. 
The differential efficacy we observed with LABAs and LAMAs is comparable to data reported 
previously, which suggest that LABAs tend to be better than LAMAs at improving symptoms 
(thus reducing rescue medication use) while LAMAs are better than LABAs at controlling 
exacerbations.[26-32] Combining both drug classes may be expected to maximise overall 
benefits, with perhaps synergistic rather than additive effects under certain conditions.[33] 
One limitation of our analyses is that we are unable to examine whether FEV1 is the 
strongest lung function predictor of improvement in patient reported outcomes.  It is certainly 
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plausible that measures more highly correlated with dynamic hyperinflation such as 
inspiratory capacity might be even better predictors of bronchodilator effects on these 
outcomes. 
5 CONCLUSIONS 
In summary, a limitation of spirometry (specifically FEV1 measurement) as a clinical endpoint 
is that it insufficiently captures the impact of COPD on a patient’s health.[2] This reiterates 
the position of the ATS/ERS Task Force, which stresses the need to measure each variable 
separately in clinical trials. Our database of over 23,000 patients provided us with a means 
to examine the interplay of these variables, and demonstrated that statistically significant 
and clinically important relationships exist at a population level between improvements in 
trough FEV1 and COPD PROs. Therapies that significantly increase FEV1 improve clinical 
and patient-reported outcomes. These beneficial relationships can be further enhanced 
when bronchodilators from different pharmacological classes are combined. 
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Additional File 1 is a supplementary figure (Figure S1: Improvements in trough FEV1 upon 
treatment: pooled data from 23 studies, by treatment group). Additional File 2 is a 
supplementary figure (Figure S2: Change in SGRQ, TDI, rescue medication use, and 
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exacerbation rate following treatment and observed change of trough FEV1 from baseline: 
linear and polynomial relationships). Additional File 3 contains four supplementary tables, 
which detail demographic and baseline characteristics by treatment and dose for all LABA-
treated patients (Table S1), LAMA-treated patients (Table S2), all LABA/LAMA- and 
placebo-treated patients (Table S3), and correlation coefficients between trough FEV1 
change from baseline and other endpoints (Table S4). Additional File 4 lists IRB approvals 
and registration details for each of the 23 studies. Additional File 5 contains an extended 
methodology section. 
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 FIGURE LEGENDS 
Figure 1: Change in SGRQ, TDI, rescue medication use, and exacerbation rate 
following treatment and observed change of trough FEV1 from baseline. Blue 
line with band, loess regression line; points with vertical line: mean with 95% CI of 
second endpoint for patients grouped into deciles of FEV1 response. 
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Figure 2: Model-based analysis by treatment Thin lines: model predictions; thick lines and 
point: representative patient population for given treatment (median and 50% PI of 
FEV1 change for treatment class). Improvements in FEV1 explain part of the 
efficacy of bronchodilator treatment on PROs. 
Figure 3: Expected change in SGRQ following treatment and observed change in FEV1 
from baseline: (a) data simulated assuming residual error of FEV1 
measurements 0.15 L and (b) data simulated assuming no error in FEV1 
measurement Simulation details: Treatments (Placebo, Trt A, Trt B and Trt C) 
give a mean improvement of lung function (∆FEV1), µtrt, of 0, 0.05, 0.1 and 0.15 L, 
respectively. Efficacy differs between patients, i, with standard deviation of 0.1L, 
µi~Norm (µtrt,0.1). ∆FEV1 has measurement error of 0.15 L, ∆ FEVi~Norm 
(µi,0.15). ∆SGRQ is equal to -40 times lung function, and has a measurement 
error of 6, ∆SGRQi~Norm (−40×µi,6). Alternative (b) assumes that ∆FEV1 
measures lung function without measurement error, ∆FEVi~Norm (µi,0.0). 
 
Figure S1 (additional file 1): Improvements in trough FEV1 upon treatment: pooled 
data from 23 studies, by treatment group. Point, thick line and thin lines depict 
the median and the 50 and 80 percentiles, respectively.  
 
Figure S2 (Additional file 2): Change in SGRQ, TDI, rescue medication use, and 
exacerbation rate following treatment and observed change of trough FEV1 
from baseline.  
In addition to the loess regression line and mean values by decile shown in Figure 
2 of the main text, linear and polynomial relationships were fitted through the data. 
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The resulting fits are shown and illustrate the similarity of the fitted linear and 
polynomial relationships.  
Blue line with band, loess regression line; points with vertical line: mean with 95% 
CI of second endpoint for patients grouped into deciles of FEV1 response; red, 
linear fit; green, yellow and orange fits of polynomials of degree 2 to 4. Fits were 
directly applied to the data except for exacerbation rates for which fits were 
applied to the mean of the rates (dots). 
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Table 2: Demographic and baseline characteristics: all patients and by drug class 
Characteristic ALL patients  
(N=23213) 
LABA/LAMA  
(N=1944) 
LABA  
(N=8852) 
LAMA  
(N=8590) 
Placebo  
(N=3287) 
Mean (SD) age, yrs 63.70 (8.61) 63.48 (8.47) 63.78 (8.75) 63.66 (8.44) 63.72 (8.73) 
Sex (Male), n (%) 16843 (72.6) 1425 (73.3) 6530 (73.8) 6234 (72.6) 2654 (69.3) 
Mean BMI (SD), kg/m2 26.17 (5.46) 26.09 (5.21) 26.13 (5.32) 26.18 (5.62) 26.28 (5.54) 
Severity of disease1 
     
 Mild, n (%) 169 (0.7) 0 100 (1.1) 24 (0.3) 45 (1.2) 
 Moderate, n (%) 10325 (44.5) 766 (39.4) 4086 (46.2) 3271 (38.1) 2202 (57.5) 
 Severe, n (%) 12044 (51.9) 1024 (52.7) 4564 (51.6) 4922 (57.3) 1534 (40.1) 
 Very severe, n (%) 582 (2.5) 151 (7.8) 62 (0.7) 352 (4.1) 17 (0.4) 
 Undefined, n (%) 93 (0.4) 3 (0.2) 40 (0.5) 21 (0.2) 29 (0.8) 
Using inhaled corticosteroids, n (%) 12441 (53.6) 1192 (61.3) 4514 (51.0) 5077 (59.1) 1658 (43.3) 
Current smoker, n (%) 9633 (41.5) 821 (42.2) 3649 (41.2) 3471 (40.4) 1692 (44.2) 
Mean (SD) FEV1 at baseline (% of 
predicted) 43.68 (13.77) 40.96 (13.81) 44.40 (13.50) 42.24 (13.59) 46.62 (14.13) 
Mean (SD) Trough FEV1 at baseline, L 1.21 (0.46) 1.14 (0.45) 1.23 (0.45) 1.17 (0.45) 1.27 (0.48) 
Percent reversibility SABA (SD) 16.16 (15.87) 19.66 (17.91) 14.60 (14.63) 16.62 (16.26) 16.99 (16.26) 
Mean rescue medication, puffs per day (SD) 3.94 (3.93) 4.82 (4.26) 3.43 (3.56) 4.32 (4.16) 3.81 (3.86) 
Exacerbation in previous 12 months, n (%) 8204 (35.3) 1010 (52.0) 2360 (26.7) 4242 (49.4) 592 (15.5) 
2GOLD 2005 
LABA, long acting β2 agonist; LAMA, long acting muscarinic antagonist; SD, standard deviation; BMI, body mass index; FEV1, forced expiratory 
volume in one second; SABA, Short-Acting β2 Agonist.   
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Table 1  Phase III/IV trials providing data on FEV1, TDI, SGRQ, rescue medication use and COPD exacerbations in relation to 
bronchodilator use 
Study  
(Trial name)  Treatments(µg) 
Total pts 
(planned) Duration 
Patient 
population Trough FEV1 times TDI times SGRQ times 
QAB149 
B2334[34] 
Dahl et al 
2010 
IND(300, 600) 
Formoterol(12) 
Placebo 1716 52 wks mod-sev COPD 
Wks 1, 2, 4, 8, 12, 16, 
20, 24, 28, 36, 44, 52 
Wks 4, 8, 12, 2, 
44, 52 
Wks 4, 8,12, 24, 
44, 52 
QAB149 
B2346a[35] 
Feldman et al 
2010 
IND(150) 
Placebo 290 12 wks mod-sev COPD Wks 1, , 4, 8, 12 NA  Wks 4, 8, 12 
GLOW 1[36] 
D’Urzo et al 
2011 
GLY(50) 
Placebo 680 26 wks mod-sev COPD 
Wks 1, 2, 4, 8, 12, 16, 
20, 26 Wks 12, 26 Wks 12, 26 
QAB149 
B2335S[37] 
QAB149 
B2335SE 
(extension)[38] 
Donohue et al, 
Chapman et al 
2011 
IND(75, 150, 300, 600) 
Formoterol(12) 
TIO(18) 
Placebo 1945 
26 wks 
with 
26 wks 
extension mod-sev COPD 
Wks 1, 2, 4, 8, 12, 16, 
21, 26, 36, 44, 52 Wks 4, 8, 12, 26 
Wks 4, 8, 12, 
26, 36, 44, 52 
         
INSIST[39] 
Korn et al 
2011 
IND(150) 
Salmeterol(50bid) 1084 12 wks mod-sev COPD Wks 1, 4, 12 Wk 12 NA  
INTENSITY[40] Buhl et al 2011 
IND(150) 
TIO(18) 1568 12 wks mod-sev COPD Wks 1, 4, 12 Wk 12 Wk 12 
QAB149 
B2354[41],[42] 
Kerwin et al 
2011 
IND(75) 
Placebo 326 12 wks mod-sev COPD Wks 1, 4, 8, 12 Wks 4, 12 Wks 4, 12 
QAB149 
B2355[41],[42] 
Kerwin et al 
2011 
IND(75) 
Placebo 326 12 wks mod-sev COPD Wks 1, 4, 8, 12 Wks 4, 12 Wks 4, 12 
 
 
INLIGHT-2[43] 
Kormann et al 
2011 
IND(150) 
Salmeterol(50bid) 
Placebo 972 26 wks mod-sev COPD 
Wks 1, 4, 8, 12, 16, 
21, 26 Wks 4 8, 12, 26 Wks 4, 8, 12, 26 
         
         
QAB149 
B1302[44] 
Kinoshita et al. 
2012 
IND(150, 300) 
Placebo 336 12 wks 
mod-sev COPD 
(Japanese) Wks 2, 4, 8, 12 Wks 4, 8, 12 Wks 4, 8, 12 
GLOW 2[45] 
Kerwin et al 
2012 
GLY(50) 
TIO(18) 
Placebo 745 52 wks mod-sev COPD 
Wks 1, 2, 4, 8, 12, 16, 
20, 26, 34, 42, 50, 52 Wks 12, 26, 52 Wks 12, 26, 52 
SHINE[28] Bateman et al. IND/GLY(110/50) 2138 26 wks mod-sev COPD Wks Wks 12, 26 Wks 12, 26 
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Study  
(Trial name)  Treatments(µg) 
Total pts 
(planned) Duration 
Patient 
population Trough FEV1 times TDI times SGRQ times 
2013 IND(150) 
GLY(50) 
TIO(18) 
Placebo 
1,2,4,8,12,16,20,26 
SPARKa[46] 
Wedzicha et 
al. 2013 
IND/GLY(110/50) 
GLY(50) 
TIO(18) 2200 64 wks sev-very sev COPD 
Wks 4, 12, 26, 38, 52, 
64 NA 
Wks 12, 26, 38, 
52, 64 
INVIGORATE[31] 
Decramer et al 
2013 
IND(150) 
TIO(18) 3500 52 wks sev COPD 
Wks 1, 2, 12, 26, 38, 
52 
Wks 12, 26, 38, 
52 
Wks 12, 26, 38, 
52 
GLOW 5[47] 
Chapman et al 
2014 
GLY(50) 
TIO(18) 660 12 wks mod-sev COPD Wks 1, 4, 12 Wks 4, 12 Wk 12 
GLOW 6[48] 
Vincken et al 
2014 
IND(150)+NVA(50) 
IND(150) 450 12 wks mod-sev COPD Wks 1, 4, 8, 12 Wk 12 Wk 12 
         
QAB149 
B2333[49] Yao et al 2014 
IND(150, 300) 
Placebo 444 26 wks 
mod-sev COPD 
(Chinese) 
Wks 1, 2, 4, 8, 12, 16, 
21, 26  Wks 8, 12, 26 Wks 8, 12, 26 
GLOW 7[50] 
Wang et al 
2015 
GLY(50) 
Placebo 450 26 wks 
mod-sev COPD 
(Chinese) Wks 1, 4,  12, 26 Wks 12, 26 Wks 12, 26 
FLIGHT 1[51] 
Mahler et al 
2015 
IND/GLY(27.5/15.6bbid) 
IND(27.5bid) 
GLY(15.6bbid) 
Placebo 1000 12 wks mod-sev COPD Wks 1, 2, 4, 8, 12 Wk 12 Wk 12 
FLIGHT 2[51] 
Mahler et al 
2015 
IND/GLY(27.5/15.6bbid) 
IND(27.5bid) 
GLY(15.6bbid) 
Placebo 1000 12 wks mod-sev COPD Wks1, 2, 4, 8, 12 Wk 12 Wk 12 
NVA237 A2317 NCT01709864 
GLY(12.5bid) 
Placebo 426 12 wks mod-sev COPD Wks 1, 2, 4, 8, 12 Wk 12 Wk 12 
NVA A2318 NCT01715298 
GLY(12.5bid) 
Placebo 426 12 wks mod-sev COPD Wks 1, 2, 4, 8, 12 Wk 12 Wk 12 
         
QAB149 B1303 NCT00876694 
IND(300) 
Salmeterol(50bid) 180 52 wks 
mod-sev COPD 
(Japanese) 
Wks 4, 8, 12, 24, 36, 
44, 52 
Wks  4, 8, 12, 
24, 36, 44, 52 
Wks 4, 8, 12, 
24, 36, 44, 52 
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Study  
(Trial name)  Treatments(µg) 
Total pts 
(planned) Duration 
Patient 
population Trough FEV1 times TDI times SGRQ times 
         
         
         
         
         
         
         
         
         
aTDI was not assessed in this study; bGlycopyrrolate 15.6µg (equivalent to 12.5µg glycopyrronium); cSGRQ was not assessed in this study. 
IND, indacaterol; GLY, glycopyrronium; TIO, tiotropium; b.i.d., twice daily; pts, patients;  mod-sev, moderate-to-severe; sev-very severe, severe-to-very severe; Wks, weeks; 
FEV1, forced expiratory volume in one second; TDI, Transition Dyspnoea index; SGRQ, St Georges Respiratory Questionnaire. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
−15
−10
−5
0
−0.4 −0.2
r = −0.16
p < 0.001
0.2 0.4 0.6
FEV1, change from baseline (L) FEV1, change from baseline (L)
FEV1, change from baseline (L) FEV1, change from baseline (L)
SG
R
Q
, c
ha
ng
e 
fr
om
 b
as
el
in
e
0
1
2
3
4
−0.4 −0.2 0.0 0.2 0.4 0.6
TD
I
−2.5
−2.0
−1.5
−1.0
−0.5
0.0
−0.4 −0.2 0.0 0.2 0.4 0.6
R
es
cu
e,
 c
ha
ng
e 
fr
om
 b
as
el
in
e 
(P
uf
fs
/D
ay
)
0.4
0.5
0.6
0.7
0.8
−0.4 −0.2 0.0 0.2 0.4 0.6
Ex
ac
er
ba
tio
n 
ra
te
 (1
/Y
ea
r)
r = 0.16
p < 0.001
r = −0.11
p < 0.001
Rs = −0.05
p < 0.001
r=–0.05
p=4.10
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
FEV1, change from baseline (L)FEV1, change from baseline (L)
FEV1, change from baseline (L)FEV1, change from baseline (L)
0.20
0.25
0.30
0.35
0.40
−0.25 0.00 0.25 0.50
Ex
ac
er
ba
tio
n 
ra
te
 (1
/Y
ea
r)

−1.50
−1.25
−1.00
−0.75
−0.25 0.00 0.25 0.50
R
es
cu
e 
m
ed
ic
at
io
n,
 c
ha
ng
e 
fr
om
 b
as
el
in
e
−9
−6
−3
−0.25 0.00 0.25 0.50
SG
R
Q
, c
ha
ng
e 
fr
om
 b
as
el
in
e
1.0
1.5
2.0
2.5
−0.25 0.00 0.25 0.50
TD
I
Treatment class Placebo LABA LAMA LABA/LAMA
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
−8
−4
0
−0.25 0.00 0.25 0.50
FEV1, change from baseline (L)
(a) (b)
SG
R
Q
, c
ha
ng
e 
fr
om
 b
as
el
in
e
Treatment class Placebo Trt A Trt B Trt C
−20
−10
0
10
−0.25 0.00 0.25 0.50
FEV1, change from baseline (L)
SG
R
Q
, c
ha
ng
e 
fr
om
 b
as
el
in
e
